Vertex Expands VX-548 Safety Profile With New Breastfeeding Study
Vertex Pharmaceuticals Inc. (VRTX) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vertex Study Tracks New Pain Drug in Breastfeeding Women
The study, titled “A Phase 1, Open-label, Single-dose Study Evaluating the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Subjects,” aims to measure how much of Vertex’s pain drug moves into breast milk. It also checks safety and infant exposure, which matters for future broad use if the drug reaches the market.
The treatment is suzetrigine, also known as VX-548 or JOURNAVX, given as an oral tablet. It is a non-opioid pain medicine designed to manage pain while avoiding the risks tied to traditional opioids.
This is an interventional Phase 1 trial with one group of participants and no randomization. Everyone receives a single dose, there is no placebo, and neither doctors nor participants are blinded, since the main goal is safety and drug level tracking.
The study was first submitted on 23 January 2026, marking the formal start of its regulatory journey. The last update on 25 February 2026 shows the record is current and confirms that the trial is still in the recruiting stage.
For investors, this update highlights Vertex’s push to de-risk VX-548 for use in more real-world settings, including breastfeeding women. Progress here can support the broader pain program narrative, where Vertex competes with other non-opioid developers and could gain an edge if safety across special groups stays clean.
Vertex shares may see sentiment support as investors value a derisked, late-stage non-opioid pain franchise with strong safety data. While this early study alone is unlikely to move the stock sharply, it adds to a steady flow of clinical signals that can underpin long-term valuation versus peers in the pain and neurology space.
The study is currently ongoing with active recruitment, and investors can track further updates and details on the ClinicalTrials portal.
To learn more about VRTX’s potential, visit the Vertex Pharmaceuticals Inc. drug pipeline page.
